NOTV

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2002, for Bioanalytical Systems, Inc. (Note: The input metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.). The company provides productivity tools, software, and research services to pharmaceutical and biotechnology firms, operating in two segments: analytical services and analytical products.

Key Financial Metrics

Note: All figures in thousands except per share data. Total debt includes revolving line of credit, capital lease obligations, and long-term debt.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 7.9% for the quarter and 9.3% for the six-month period compared to the prior year. This was driven primarily by a 21.9% increase in product revenue (quarterly) due to sales of Culex automated blood sampling devices.
• Margin Compression: Gross profit decreased despite revenue growth. Cost of service revenue rose to 65.8% of service revenue (from 58.9% prior year) due to staffing and wage increases. Cost of product revenue rose to 46.0% (from 33.3%) due to product mix changes.
• Operating Expenses: General and administrative expenses increased 6.2% (quarterly) and 17.9% (six-month) primarily due to organizational restructuring of preclinical operations. R&D expenses decreased due to increased grant reimbursements.
• Cash Flow: Net cash provided by operating activities turned negative at $(0.717) million for the six months ended March 31, 2002, compared to $0.937 million in the prior year. This was driven by a $1.052 million increase in accounts receivable and a $0.972 million decrease in accounts payable.
• Investing Activity: Cash used for investing activities increased to $1.477 million (six months) from $0.618 million, largely due to construction at the preclinical site and lab equipment purchases.

Outlook, Risks, and Unusual Items

• Capital Expenditures: The company signed a letter of intent to expand facilities in Evansville, Indiana, with a commitment of approximately $2.5 million, expected to be completed in December 2002. A $250,000 deposit was made on a building purchase near headquarters.
• Debt Renewal: The revolving line of credit ($3.5 million limit) was renewed to expire April 1, 2004. The interest rate remains at the bank's prime rate minus 25 basis points.
• Accounting Changes: The company will adopt SFAS No. 142 (Goodwill) effective October 1, 2002, which will stop goodwill amortization. This is expected to increase net income by approximately $77,000 annually.
• Liquidity: Management believes cash from operations and the existing line of credit are sufficient to fund working capital and capital expenditure requirements.
• Forward-Looking Statements: The filing includes standard disclaimers regarding risks associated with strategic plans, profitability, and industry trends.

Investor Verification Checklist

• Accounts Receivable Aging: Verify the collectability of the $5.318 million receivable balance, which increased significantly and contributed to negative operating cash flow.
• Product Mix Sustainability: Assess whether the margin compression in product revenue (due to Culex device sales) is temporary or indicative of a structural shift in profitability.
• Debt Covenants: Confirm compliance with financial ratios required by the revolving line of credit and commercial mortgage.
• Capital Project ROI: Evaluate the projected return on the $2.5 million facility expansion and the new building purchase.
• Service Cost Control: Monitor the trend of service revenue costs, which rose to 65.8% of revenue, to ensure staffing costs do not further erode margins.